Literature DB >> 19346857

Imaging of small hepatic metastases of colorectal carcinoma: how to use superparamagnetic iron oxide-enhanced magnetic resonance imaging in the multidetector-row computed tomography age?

Utaroh Motosugi1, Tomoaki Ichikawa, Hiroto Nakajima, Hironobu Sou, Mika Sano, Katsuhiro Sano, Tsutomu Araki, Hiroshi Iino, Hideki Fujii, Tadao Nakazawa.   

Abstract

PURPOSE: To compare the accuracy of dynamic contrast-enhanced multidetector-row computed tomography (CT) and superparamagnetic iron oxide-enhanced magnetic resonance imaging (MRI) in the evaluation of small hepatic metastases of colorectal carcinoma.
MATERIALS AND METHODS: Of 94 patients with colorectal carcinoma analyzed, 76 hepatic metastases (<2 cm) were diagnosed in 17 patients. Superparamagnetic iron oxide (SPIO)-magnetic resonance (precontrast and postcontrast MRI) and dynamic contrast-enhanced multidetector-row CT (dynamic CT [precontrast, arterial, portal-venous, and delayed phase]) were evaluated. The alternative free-response receiver operating characteristic analysis was performed, and the sensitivities and positive predictive values were analyzed.
RESULTS: The Az values and sensitivities of portal-venous phase CT, dynamic CT, and SPIO-MRI (0.62/59%, 0.69/61%, and 0.67/61%) were identical. The mean positive predictive value of dynamic CT (82%) was inferior to that of SPIO-MRI (91%).
CONCLUSIONS: The diagnostic ability of dynamic CT is identical to that of SPIO-MRI in Az value and sensitivity. Superparamagnetic iron oxide-MRI should be recommended only if an equivocal lesion is detected by dynamic CT.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19346857     DOI: 10.1097/RCT.0b013e31817f5c82

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  7 in total

1.  Value of visual inspection, bimanual palpation, and intraoperative ultrasonography during hepatic resection for liver metastases of colorectal carcinoma.

Authors:  Shojiro Hata; Hiroshi Imamura; Taku Aoki; Takuya Hashimoto; Masaaki Akahane; Kiyoshi Hasegawa; Yoshifumi Bekku; Yasuhiko Sugawara; Masatoshi Makuuchi; Norihiro Kokudo
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

2.  Imaging for suspected colorectal cancer in frail and elderly patients.

Authors:  L Bacigalupo; F Paparo
Journal:  Tech Coloproctol       Date:  2013-08-09       Impact factor: 3.781

3.  A case of a large cholangiolocellular carcinoma.

Authors:  Moe Kadono; Kiminori Kimura; Jun Imamura; Shunichi Saeki; Masanao Kurata; Goro Honda; Koji Tsuruta; Shinichiro Horiguchi; Seishu Hayashi
Journal:  Clin J Gastroenterol       Date:  2011-08-07

4.  Staging colorectal cancer with the TNM 7(th): the presumption of innocence when applying the M category.

Authors:  Giacomo Puppa; Graeme Poston; Per Jess; Guy F Nash; Kenneth Coenegrachts; Axel Stang
Journal:  World J Gastroenterol       Date:  2013-02-28       Impact factor: 5.742

Review 5.  Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis.

Authors:  Charlotte S van Kessel; Constantinus F M Buckens; Maurice A A J van den Bosch; Maarten S van Leeuwen; Richard van Hillegersberg; Helena M Verkooijen
Journal:  Ann Surg Oncol       Date:  2012-03-07       Impact factor: 5.344

6.  The feasibility of superparamagnetic iron oxide-enhanced magnetic resonance imaging for assessing liver lesions in patients with contraindications for iodine CT contrast media or gadolinium-based MR contrast media: a retrospective case-control study.

Authors:  Chishio Kurata; Kazuhiro Saito; Natsuhiko Shirota; Yoichi Araki; Katsutoshi Sugimoto; Yu Tajima; Daisuke Yunaiyama
Journal:  Quant Imaging Med Surg       Date:  2022-09

7.  MR imaging in patients with suspected liver metastases: value of liver-specific contrast agent gadoxetic acid.

Authors:  Kyung Hee Lee; Jeong Min Lee; Ji Hoon Park; Jung Hoon Kim; Hee Sun Park; Mi Hye Yu; Jeong-Hee Yoon; Joon Koo Han; Byung Ihn Choi
Journal:  Korean J Radiol       Date:  2013-11-05       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.